Journal of Medicinal Chemistry · 2012 · 248 citations · 50 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyDrug DiscoveryApoptosis In CancerApoptosis PharmacologyApoptotic SignalingDeath ReceptorsEnzyme InhibitionLigand BindingAnti-apoptotic AgentsApoptosis TargetingIap AntagonistsIap-mediated Apoptosis InhibitionInhibitor Of Apoptosis ProteinsProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 Inhibitors
A series of compounds were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac. Compound 1 (GDC-0152) has the best profile of these compounds; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with K(i) values of 28, 14, 17, and 43 nM, respectively. These compounds promote degradation of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells. Compound 1 inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model. Compound 1 was advanced to human clinical trials, and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested. Mean plasma clearance in humans was 9 ± 3 mL/min/kg, and the volume of distribution was 0.6 ± 0.2 L/kg.
50